Herrmann K, Engst W, Florian S, Lampen A, Meinl W, Glatt H R
German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke , Department of Nutritional Toxicology , Nuthetal , Germany.
Federal Institute for Risk Assessment (BfR) , Department of Food Safety , Berlin , Germany . Email:
Toxicol Res (Camb). 2016 Feb 12;5(3):808-815. doi: 10.1039/c5tx00358j. eCollection 2016 May 1.
Methyleugenol, present in herbs and spices, has demonstrated carcinogenic activity in the liver and, to a lesser extent, in extrahepatic tissues of rats and mice. It forms DNA adducts after hydroxylation and sulphation. As previously reported, hepatic DNA adduct formation by methyleugenol in mice is strongly affected by their sulphotransferase (SULT) 1A status. Now, we analysed the adduct formation in extrahepatic tissues. The time course of the adduct levels was determined in transgenic (tg) mice, expressing human SULT1A1/2, after oral administration of methyleugenol (50 mg per kg body mass). Nearly maximal adduct levels were observed 6 h after treatment. They followed the order: liver > caecum > kidney > colon > stomach > small intestine > lung > spleen. We then selected liver, caecum, kidney and stomach for the main study, in which four mouse lines [wild-type (wt), Sult1a1-knockout (ko), tg, and humanized (ko-tg)] were treated with methyleugenol at varying dose levels. In the liver, caecum and kidney, adduct formation was nearly completely dependent on the expression of SULT1A enzymes. In the liver, human SULT1A1/2 led to higher adduct levels than mouse Sult1a1, and the effects of both enzymes were approximately additive. In the caecum, human SULT1A1/2 and mouse Sult1a1 were nearly equally effective, again with additive effects in tg mice. In the kidney, only human SULT1A1/2 played a role: no adducts were detected in wt and ko mice even at the highest dose tested and the adduct levels were similar in tg and ko-tg mice. In the stomach, adduct formation was unaffected by the SULT1A status.
(i) the SULT1A enzymes only affected adduct formation in those tissues in which they are highly expressed (mouse Sult1a1 in the liver and caecum, but not in the kidney and stomach; human SULT1A1/2 in the liver, caecum and kidney, not in the stomach of tg mice and humans), indicating a dominating role of local bioactivation; (ii) the additivity of the effects of both enzymes in the liver and caecum implies that the enzyme level was limiting in the adduct formation; (iii) SULT1A forms dominated the activation of methyleugenol in several tissues, but non-Sult1a1 forms or SULT-independent mechanisms were involved in its adduct formation in the stomach.
存在于草药和香料中的甲基丁香酚已在大鼠和小鼠的肝脏中表现出致癌活性,在肝外组织中的致癌活性较低。它在羟基化和硫酸化后形成DNA加合物。如先前报道,小鼠肝脏中甲基丁香酚诱导的DNA加合物形成受到其磺基转移酶(SULT)1A状态的强烈影响。现在,我们分析了肝外组织中的加合物形成情况。在口服给予甲基丁香酚(每千克体重50毫克)后,测定了表达人SULT1A1/2的转基因(tg)小鼠中加合物水平的时间进程。治疗后6小时观察到几乎最高的加合物水平。它们的顺序为:肝脏>盲肠>肾脏>结肠>胃>小肠>肺>脾脏。然后我们选择肝脏、盲肠、肾脏和胃进行主要研究,在该研究中,用不同剂量水平的甲基丁香酚处理四种小鼠品系[野生型(wt)、Sult1a1基因敲除(ko)、tg和人源化(ko-tg)]。在肝脏、盲肠和肾脏中,加合物形成几乎完全依赖于SULT1A酶的表达。在肝脏中,人SULT1A1/2导致的加合物水平高于小鼠Sult1a1,并且两种酶的作用大致呈加和性。在盲肠中,人SULT1A1/2和小鼠Sult1a1的效果几乎相同,在tg小鼠中同样具有加和效应。在肾脏中,只有人SULT1A1/2起作用:即使在测试的最高剂量下,wt和ko小鼠中也未检测到加合物,tg和ko-tg小鼠中的加合物水平相似。在胃中,加合物形成不受SULT1A状态的影响。
(i)SULT1A酶仅在其高表达的组织中影响加合物形成(小鼠Sult1a1在肝脏和盲肠中高表达,但在肾脏和胃中不高表达;人SULT1A1/2在肝脏、盲肠和肾脏中高表达,在tg小鼠和人的胃中不高表达),表明局部生物活化起主导作用;(ii)两种酶在肝脏和盲肠中的作用具有加和性,这意味着酶水平在加合物形成中起限制作用;(iii)SULT1A形式在几种组织中主导了甲基丁香酚的活化,但非Sult1a1形式或不依赖SULT的机制参与了其在胃中的加合物形成。